We’re delighted to welcome Orion Pharma to the Babraham Research Campus community. The pharmaceutical company, headquartered in Finland, has opened its new Biologics Research & Development Centre on site, further strengthening the Campus’s reputation as one of the UK’s leading hubs for bioscience innovation.

A recent Business Weekly article highlights how Orion is already benefitting from being based at Babraham, with access to world-class scientific talent and the Cambridge Ecosystem.

“Cambridge is a place where the discovery of biologics truly started… We want to be part of this fantastic environment, tapping into the world-class talent and scientific collaboration opportunities it offers,” said Outi Vaarala, Orion’s EVP of R&D.

Orion has quickly established itself at the Campus, recruiting more than 20 researchers and aiming to grow to around 50 by 2027–2028. The team reports being “positively surprised” by both the quality of recruitment locally, a reflection of Cambridge’s exceptional talent pool and the benefits of being part of the Babraham ecosystem.

Their decision to locate at Babraham complements Orion’s long-established small molecule research base in Finland and marks a major step in the company’s global expansion into biologics.

For Babraham Research Campus, Orion’s arrival reinforces the Campus’s unique value proposition: a place where science thrives through proximity, collaboration, and community. Their presence adds to the growing momentum of companies working in biologics, therapeutics and translational research, and opens up new opportunities for knowledge exchange and partnership across the Campus.

We look forward to seeing Orion flourish as part of our community and to the collaborations that will undoubtedly follow.